Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 408 across all filing types
Latest filing 2024-12-23 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Results of RetailBook Offer
Share Issue/Capital Change Classification · 99% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service) of the London Stock Exchange, indicated by the 'RNS Number' and the concluding boilerplate text referencing RNS and the FCA. The content details the 'Results of RetailBook Offer,' specifying gross proceeds raised (£96,715.83) from the issue of new shares (3,223,861 RetailBook Offer Shares) as part of a larger financing effort contingent on a General Meeting. This announcement concerns fundraising and capital structure changes, specifically the results of an offer for shares. While it relates to capital, the primary nature of the document is a regulatory disclosure of a completed offering event, which often falls under general regulatory announcements or specific capital/financing updates. Given the explicit mention of raising proceeds via the issue of shares, 'Capital/Financing Update' (CAP) is highly relevant. However, since this is a formal, time-sensitive announcement disseminated through the official regulatory news service (RNS) detailing the outcome of a specific corporate action (share offer), and it is not a comprehensive report (like 10-K or IR), it fits well within the scope of a general regulatory filing or a specific financing announcement. Since 'CAP' specifically covers fundraising/financing activities, it is the most precise fit for the core subject matter (raising gross proceeds via share issue). The document is not merely announcing that a report is attached (RPA), but is the report/result itself.
2024-12-23 English
RetailBook Offer
Capital/Financing Update Classification · 95% confidence The document is an official announcement released via RNS (RNS Number : 1732P) on December 6, 2024. It details a conditional 'RetailBook Offer' of new ordinary shares at a specific price (3.0 p per share) and mentions associated actions like a Subscription and a future General Meeting (December 24, 2024) for passing resolutions. This announcement is clearly communicating a corporate action related to capital structure (issuing new shares) and is being disseminated through regulatory channels (RNS). Since it is an announcement about a capital/financing activity (share issuance/offer) and is distributed via RNS, the most specific applicable code is 'CAP' (Capital/Financing Update). However, given the nature of the distribution (RNS Number) and the fact that it is a general regulatory announcement detailing a specific corporate action, 'RNS' (Regulatory Filings) is also a strong candidate if 'CAP' is reserved for more formal prospectus-like filings. Since the core subject is a share offer/capital raise, 'CAP' is the primary fit. If the document were purely a notice that a report was published, 'RPA' would apply, but this document contains the substance of the capital raise details. Therefore, 'CAP' is the best fit for the content, even though it is distributed via RNS.
2024-12-06 English
Subscription by AOP Health to raise US$10 million
Regulatory Filings Classification · 98% confidence The document is an official announcement from Shield Therapeutics plc, identified by the RNS Number and the date format typical of regulatory news services. The content details a significant capital raising event ('Subscription by AOP Health International Management AG... to raise US$10 million') and a 'RetailBook Offer'. Crucially, it also includes a 'Notice of General Meeting' and discusses the 'Proposed waiver of obligations under Rule 9 of the Takeover Code'. The combination of a major financing event requiring shareholder approval (General Meeting) and specific regulatory considerations (Takeover Code Rule 9 waiver) strongly indicates a filing related to corporate actions and financing. Since it announces the terms of a subscription and a related shareholder meeting, it falls under Capital/Financing Update (CAP). Although it mentions a Circular and General Meeting, the primary focus is the financing structure itself, not just the proxy materials (DEF 14A/PSI) or the meeting results (DVA). It is not a full Annual Report (10-K) or an Interim Report (IR), but a specific announcement about raising capital.
2024-12-06 English
Business Update
Regulatory Filings Classification · 99% confidence The document is identified by the header 'RNS Number : 0479N' and concludes with information about RNS, the news service of the London Stock Exchange, which acts as a Primary Information Provider. The content provides a 'Business Update' covering clinical trial recruitment completion, financing progress, and sales performance, which are typical elements of a timely corporate announcement. Since it is a general, timely update disseminated via the RNS system and does not fit the specific criteria for an Earnings Release (ER), Interim Report (IR), or a specific regulatory filing like 10-K, it best fits the general regulatory announcement category, which is RNS.
2024-11-21 English
Q3 Trading Update
Earnings Release Classification · 99% confidence The document is titled 'Q3 Trading Update' and provides unaudited financial highlights (net revenues, prescription numbers) for the third quarter of 2024. This content structure—a brief update on recent performance metrics, often released before a full quarterly report—aligns best with the Earnings Release (ER) definition, which covers initial announcements of periodical financial results (key highlights only). Although it contains some forward-looking statements and financing details, the core purpose is the Q3 performance summary. It is not a full comprehensive report (IR) or a management discussion (MDA), but rather the initial release of results highlights. Q3 2024
2024-10-29 English
Results from Phase 3 paediatric study
Regulatory Filings Classification · 98% confidence The document is identified by the header 'RNS Number : 4852F' and concludes with standard RNS closing information, indicating it is a regulatory announcement distributed via the London Stock Exchange's news service. The content details the results of a Phase 3 clinical trial for a drug (ferric maltol) and explicitly states that this data will support future filing obligations with the US FDA and EMA. This type of announcement, which communicates material, non-financial operational/clinical updates to the market via an official regulatory channel, fits best under the general 'Regulatory Filings' category (RNS) as it is not a formal financial report (like 10-K or IR), an earnings release (ER), or a specific management discussion (MDA). It is a general regulatory news service release.
2024-09-25 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.